Home/Filings/4/0001231919-25-000596
4//SEC Filing

RA Capital Healthcare Fund LP 4

Accession 0001231919-25-000596

CIK 0001680581other

Filed

Dec 9, 7:00 PM ET

Accepted

Dec 10, 4:42 PM ET

Size

15.1 KB

Accession

0001231919-25-000596

Insider Transaction Report

Form 4
Period: 2025-12-08
Transactions
  • Sale

    Common Stock

    2025-12-08$13.33/sh1,377,020$18,355,6778,852,079 total(indirect: See footnotes)
  • Sale

    Common Stock

    2025-12-08$14.28/sh2,706,397$38,647,3496,145,682 total(indirect: See footnotes)
  • Sale

    Common Stock

    2025-12-08$14.98/sh91,722$1,373,9966,053,960 total(indirect: See footnotes)
Transactions
  • Sale

    Common Stock

    2025-12-08$13.33/sh1,377,020$18,355,6778,852,079 total(indirect: See footnotes)
  • Sale

    Common Stock

    2025-12-08$14.28/sh2,706,397$38,647,3496,145,682 total(indirect: See footnotes)
  • Sale

    Common Stock

    2025-12-08$14.98/sh91,722$1,373,9966,053,960 total(indirect: See footnotes)
Transactions
  • Sale

    Common Stock

    2025-12-08$13.33/sh1,377,020$18,355,6778,852,079 total(indirect: See footnotes)
  • Sale

    Common Stock

    2025-12-08$14.28/sh2,706,397$38,647,3496,145,682 total(indirect: See footnotes)
  • Sale

    Common Stock

    2025-12-08$14.98/sh91,722$1,373,9966,053,960 total(indirect: See footnotes)
Transactions
  • Sale

    Common Stock

    2025-12-08$13.33/sh1,377,020$18,355,6778,852,079 total(indirect: See footnotes)
  • Sale

    Common Stock

    2025-12-08$14.28/sh2,706,397$38,647,3496,145,682 total(indirect: See footnotes)
  • Sale

    Common Stock

    2025-12-08$14.98/sh91,722$1,373,9966,053,960 total(indirect: See footnotes)
Footnotes (5)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.81 to $13.8099 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • [F3]Held directly by the Fund.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.81 to $14.805 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.81 to $15.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

Fulcrum Therapeutics, Inc.

CIK 0001680581

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001315082

Filing Metadata

Form type
4
Filed
Dec 9, 7:00 PM ET
Accepted
Dec 10, 4:42 PM ET
Size
15.1 KB